Printer Friendly

ADVANCED BIOLOGICAL SYSTEMS, AIDS TREATMENT SPONSOR, COMPLETES $800,000 IN PRIVATE PLACEMENTS

 ADVANCED BIOLOGICAL SYSTEMS, AIDS TREATMENT SPONSOR,
 COMPLETES $800,000 IN PRIVATE PLACEMENTS
 SALT LAKE CITY, April 8 /PRNewswire/ -- Advanced Biological Systems, Inc. (OTC: Bulletin Board) today announced the company has completed a series of private placements in Europe totalling US$800,000 through its Zurich-based investment banker, Rolcan Finance, Ltd. Emanuel A. Floor, chief executive officer of the company, said a portion of the proceeds of the securities sale will be used to satisfy prior obligations. The balance of the new capital has been ear-marked to accelerate the company's dual business strategy calling for the opening of AIDS treatment clinics in suitable jurisdictions and sponsorship of additional scientific studies of the non-toxic, plant-based drugs, Carciviren-V and Rovital-V, leading to registration of the products in other areas.
 Advanced Biological Systems (ABS) holds exclusive Western Hemisphere, Asia/Pacific, and U.K. distribution rights for both compounds which have repeatedly demonstrated a stimulative effect on the human immune system, while reducing the activation and replication of the AIDS-causing virus.
 The first ABS clinic in the Western Hemisphere, using the plant- based pharmaceuticals developed by Swiss physician Dr. Jozsef Roka, is scheduled to open by the end of April in the Caribbean Basin. A second clinic, which the company expects to open by the end of May, is currently being developed in Mexico.
 In Europe, Advanced Biological Systems is working with a group of London-based physicians who are testing the drugs for anti-oxidant and anti-viral qualities related to future treatment programs and proposed clinical trials.
 Details are also being finalized with authorities at the University Hospital of the West Indies in Kingston, Jamaica, for that institution to undertake major independent pilot and controlled double blind studies of the drugs.
 During the past two years, Roka and his associate have treated approximately 300 AIDS patients at clinics in Zurich, Switzerland, and
Tanzania, Africa. ABS has recently published an "Interim Patient


Report" based on independent interviews with 24 of those patients who testify they have been helped by the Roka treatment, along with a preliminary scientific review of how Carciviren-V and Rovital-V work.
 According to Floor, patients have reported: 1) substantial remission of AIDS symptoms within a relatively short period after treatment began; 2) a return to normal body weight and general good health; 3) the ability to resume regular work and normal activities; and 4) a reduction, in many cases, of measurable serumantigen activity.
 Advanced Biological Systems, a publicly-owned Delaware corporation traded-over-the-counter, has been approved for listing on NASDAQ by the NASD pending compliance with the system's minimum price requirement.
 -0- 4/8/92
 /CONTACT: Emanuel A. Floor of Advanced Biological Systems, 810-521-8000, Cameron King of Gavin Anderson, 212-921-1060/ CO: Advanced Biological Systems Inc. ST: Utah IN: MTC SU:


SH -- NY021 -- 6121 04/08/92 09:43 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1992
Words:463
Previous Article:FIRST FLORIDA BANK, N.A. ANNOUNCES NEW FINANCIAL AND DATA PROCESSING UNIT -- FPI
Next Article:PLUM CREEK TIMBER COMPANY, L.P. ANNOUNCES QUARTERLY DISTRIBUTION TO UNITHOLDERS AND HIGHER FIRST QUARTER EARNINGS


Related Articles
ADVANCED BIOLOGICAL SYSTEMS TO OPEN AIDS TREATMENT CLINIC IN LONDON, WILL ALSO TREAT SELECTED PATIENTS FREE IN RESEARCH STUDY
JAMAICAN RESEARCHERS GIVE GREEN LIGHT TO HUMAN CLINICAL TRIALS FOR PROMISING PLANT-BASED AIDS DRUG DEVELOPED IN SWITZERLAND
ADVANCED BIOLOGICAL SYSTEMS COMPLETES $2 MILLION PRIVATE PLACEMENT; INTENDS TO FILE FOR NASDAQ LISTING, PROCEED WITH CLINIC & RESEARCH PLANS
LIDAK PHARMACEUTICALS COMPLETES PRIVATE PLACEMENT
ADVANCED BIOLOGICAL SYSTEMS REPORTS ADDITIONAL, FAVORABLE TOXICITY TESTS FOR PLANT-BASED AIDS DRUGS, C-1983 AND R-1103
AMERICAN BIODYNAMICS ANNOUNCES PRIVATE PLACEMENT OF $800,000 IN RESTRICTED COMMON STOCK
UNIVERSITY OF LONDON INDEPENDENT LAB STUDIES VERIFY POWERFUL ANTI- OXIDANT PROPERTIES OF ADVANCED BIOLOGICAL SYSTEMS' AIDS COMPOUNDS
ADVANCED BIOLOGICAL SYSTEMS' LICENSEE BEGINS TREATING AIDS PATIENTS IN THE CARIBBEAN; ROKA TREATMENT USES PLANT-BASED THERAPEUTICS
FREE RADICAL SCIENCES INC. COMPLETES $6.5 MILLION FINANCING
Ciro International, Inc. Announces Agreement With Advanced Bio/Chem, Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters